The Cancer Letter

Inside information on cancer research and drug development

ClinicalTrials & Tribulations

MRI-guided radiotherapy for prostate cancer: Lessons from the MIRAGE trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The National Cancer Institute defines precision medicine in cancer as a strategy that “uses specific information about a person’s tumor to help make a diagnosis, plan treatment, find out how well treatment is working, or make a prognosis.”1 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Amar U. Kishan, MD
Associate professor, Chief of Genitourinary Oncology Service, Vice chair of clinical and translational research, Department of Radiation Oncology, University of California, Los Angeles
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

AI may be more accurate vs. traditional methods at classifying patients into prostate cancer risk groups

For localized prostate cancer, multimodal artificial intelligence models have revealed a more accurate way to assess prostate cancer risk.  By combining advanced artificial intelligence with digital pathology images and clinical data, researchers developed a way to approach risk classification that outperforms traditional methods. These findings were published in JCO Precision Oncology. The research found that...

Byline
Amar U. Kishan, MD
Associate professor, Chief of Genitourinary Oncology Service, Vice chair of clinical and translational research, Department of Radiation Oncology, University of California, Los Angeles
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account